Abstracts, 5th DICID Methods: A model of HBV is described by: x, y, v, z which represent uninfected cells, infected cells, free virus, and CTL cells respectively. Here the infected cells were divided into two parts with one part having drug resistance and the other part having none. The model includes 11 parameters : l, d, b, a, p, k1, k2, u, c, b, t. During treatment of AD, we chose {l, d, b, a, p, k1, k2, u, c, b, t} = {4.621e5, 1, 0.93, 0.08, 0.35 Background: The prevalence and infection hepatitis B virus is a serious problem in the world. Recent studies showed that the PD-1/PD-L pathway contributed directly to T cell dysfunction and lack of viral control in established chronic infection. In the present study, we try to improve the immune effect of HBsAg vaccination in HBV transgenic mice by blocking PD-1/PD-L pathway in vivo and to seek new methods for the treatment of chronic hepatitis B. Methods: Fifteen HBV Tg mice were randomized into three groups with 5 mice each, and designated as HBsAg vaccine group, vaccine and B7-H1 group and control group, respectively. The anti-HBs of the three groups were detected by ELISA. The splenocytes of the mice were stimulated with HBsAg (10mg/ml). The concentrations of IL-2 and IFN-g were detected by ELISA. The number of IFN-g secreting cells was measured by ELISPOT. Results: The anti-B7-H1 in serum was detected in the mice immunized with B7-H1 and the antibody titer increased with the immune times. There was no difference of antiHBs positive rate between HBsAg group and HBsAg+B7-H1 group at 6 th week and 8 th week after immunization. Concentrations of IL-2 and IFN-g were elevated in both HBsAg group and HBsAg + B7-H1 group than that in control group (P < 0.05). Moreover, The numbers of HBs-specifc IFN-g secreting T cells is also increased in both the HBsAg group and HBsAg + B7-H1 group when compared with the control group, and the outcomes showed no difference between the two experimental groups (P > 0.05). Conclusion: (1) HBsAg vaccine can increase the cellular and humoral immune response in HBV Tg mice and reconstruct immune response to HBsAg. (2) B7-H1 vaccine can not enhance the humoral and cell immune responses in HBV Tg mice immunized with HBsAg.
Background: The prevalence and infection hepatitis B virus is a serious problem in the world. Recent studies showed that the PD-1/PD-L pathway contributed directly to T cell dysfunction and lack of viral control in established chronic infection. In the present study, we try to improve the immune effect of HBsAg vaccination in HBV transgenic mice by blocking PD-1/PD-L pathway in vivo and to seek new methods for the treatment of chronic hepatitis B. Methods: Fifteen HBV Tg mice were randomized into three groups with 5 mice each, and designated as HBsAg vaccine group, vaccine and B7-H1 group and control group, respectively. The anti-HBs of the three groups were detected by ELISA. The splenocytes of the mice were stimulated with HBsAg (10mg/ml). The concentrations of IL-2 and IFN-g were detected by ELISA. The number of IFN-g secreting cells was measured by ELISPOT. Results: The anti-B7-H1 in serum was detected in the mice immunized with B7-H1 and the antibody titer increased with the immune times. There was no difference of antiHBs positive rate between HBsAg group and HBsAg+B7-H1 group at 6 th week and 8 th week after immunization. Concentrations of IL-2 and IFN-g were elevated in both HBsAg group and HBsAg + B7-H1 group than that in control group (P < 0.05). Moreover, The numbers of HBs-specifc IFN-g secreting T cells is also increased in both the HBsAg group and HBsAg + B7-H1 group when compared with the control group, and the outcomes showed no difference between the two experimental groups (P > 0.05). Results: Hepatic encephalopathy, pulmonary infection, upper gastrointestinal bleeding (UGIB), albumin, AST, creatinine, international normalized ratio (INR) were determined to be independent risk factors (P < 0.01); accordingly, the prognostic index (PI) = 4.98 × hepatic encephalopathy + 4.57 × pulmonary infection + 4.41 × upper gastrointestinal bleeding Objective: The aim of this study was to investigate the relationship between HBsAg, HBcAg expression and serum HBV DNA level. Methods: The expression of HBsAg, HBcAg in the livers of 140 patients with chronic hepatitis B was detected by immunohistochemistry. And the level of serum hepatitis B virus DNA (HBV DNA) was tested. Statistical significance was assessed using One-Way analysis of variance (ANOVA). Results: Serum HBV DNA level in 13 patients with HBsAg (~±), 108 patients with (+~++) and 19 patients with (+++~++++) was 5.313±1.874 copies log 10 /ml, 6.010±2.016 copies log 10 /ml and 5.664±1.548 copies log 10 /ml respectively (P = 0.408). Serum HBV DNA level in 42 patients with HBsAg (~±), 79 patients with (+~++) and 19 patients with (+++~++++) was 5.886±1.997 copies log 10 /ml, 5.968±2.020 copies log 10 /ml and 5.634±1.551 copies log 10 /ml respectively (P = 0.800). Objectives: To analyze the causes of the patients with chronic Hepatitis B without taking antiviral therapy and the strategies of dealing with it. Method: We make long-termed observation on the patients with chronic Hepatitis B Virus (HBV) infection, who were voluntarily to be followed up in our clinic department, and analyze statistically the objective and subjective causes of patient without taking antiviral therapy. Results: In total eligible 951 cases, 424 cases didn't receive the antiviral therapy. 105 out of 424 cases had the indications of the antiviral therapy (105/424, 24.8%), the other 319 cases had no indications of the therapy (319/424, 75.2%). The ratio of female (124/202, 61.4%) who didn't get the antiviral therapy was significant higher than that of male (300/749, 40.0%). 49 out of 105 cases who had the indications of the antiviral therapy worried about the unhealthful effect on their fertility by the antiviral drugs and put off antiviral therapy (49/ Results: The serum HBV DNA loads in HBeAg-positive group with inflammation grades G 0 1 (6 patients), G 2 (74 patients) and G 3 4 (25 patients) were 5.580±1.098 copies log 10 /ml, 6.520±2.004 copies log 10 /ml and 6.950±1.467 copies log 10 /ml respectively. There was no significant difference in patients of three inflammation grades (P = 0.250). The serum HBV DNA loads in HBeAg-positive group with liver tissues fibrosis stages of S 0 1 (23 patients), S 2 (56 patients), S 3 4 (26 patients) were 6.599±1.832 copies log 10 /ml, 6.559±2.012 copies log 10 /ml, 6.562±1.601 copies log 10 /ml respectively, the difference was not significant (P = 0.996). The serum HBV DNA loads in HBeAg-negative group with inflammation grades G 0 1 (8 patients), G 2 (17 patients) and G 3 4 (28 patients) were 2.132±1.875 copies log 10 /ml, 4.745±2.250 copies log 10 /ml and 5.581±2.305 copies log 10 /ml respectively. The serum HBV DNA level in patients with G 2 and G 3 4 inflammation grades was significant higher than in patients with G 0 1 inflammation grades (P = 0.001). The serum HBV DNA loads in HBeAg-negative group with liver tissues fibrosis stages of S 0 1 (10 patients), S 2 (45 patients), S 3 4 (18 patients) were 2.689±3.225 copies log 10 /ml, 5.127±1.833 copies log 10 /ml, 5.375±2.410 copies log 10 /ml respectively. The serum HBV DNA level in patients with fibrosis stages of S 2 and S 3 4 was significant higher than in patients with fibrosis stages of S 0 1 (P = 0.005). Conclusions: The serum HBV DNA level does not correlate with the inflammation grades and fibrosis stages of liver tissues in HBeAg-positive patients. The serum HBV DNA loads display a positive correlation with the inflammation grades and fibrosis stages of liver tissues in HBeAg-negative patients.
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